Genzyme’s Asian Expertise Drives Alnylan Co-Development Pact For TTR Candidates
This article was originally published in PharmAsia News
RNAi pioneer Alnylan is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.
You may also be interested in...
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.
The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.